title: Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria.
authors.affiliation: Department of Medicine, University of Virginia Health System, Charlottesville, Va. Electronic address: TVP9Z@hscmail.mcc.virginia.edu.
authors.forename: Thamiris
authors.initials: T
authors.lastname: Palacios
authors.affiliation: Department of Medicine, University of Virginia Health System, Charlottesville, Va.
authors.forename: Leland
authors.initials: L
authors.lastname: Stillman
authors.affiliation: Department of Medicine, University of Virginia Health System, Charlottesville, Va; Department of Microbiology, University of Virginia Health System, Charlottesville, Va.
authors.forename: Larry
authors.initials: L
authors.lastname: Borish
authors.affiliation: Department of Medicine, University of Virginia Health System, Charlottesville, Va.
authors.forename: Monica
authors.initials: M
authors.lastname: Lawrence
mesh_terms: D000328:Adult; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D015549:Basophil Degranulation Test / Q000379:methods; D001491:Basophils / Q000276:immunology*; D015415:Biomarkers / Q000032:analysis; D002908:Chronic Disease; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases / Q000032:analysis*; D011755:Pyrophosphatases / Q000032:analysis*; D015203:Reproducibility of Results; D012189:Retrospective Studies; D014581:Urticaria / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology
chemical_list: D018926:Anti-Allergic Agents; D015415:Biomarkers; C427944:ENPP3 protein, human; D000069444:Omalizumab; D010727:Phosphoric Diester Hydrolases; D011755:Pyrophosphatases